Episode # 28 • 07 Oct 2025
How Biomarkers Enhance Precision Medicine in Non-Muscle Invasive Bladder Cancer
As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC).
This podcast is supported by
Timestamps
00:00 - Introduction
05:25 - Challenges with Current Biomarkers
08:10 - New Biomarkers and Genomic Classifiers
21:10 - AI and Pathology in Bladder Cancer
35:13 - Screening and Future Directions
41:20 - Challenges and Future Directions in Bladder Cancer Surveillance
57:51 - Conclusion
Resources
You may also like
More about this episode
The conversation covers the current challenges of interpreting positive biomarkers without clinical correlates, the gold standard of biopsies, and the potential of various biomarkers such as urine cytology, FISH, and newer genomic tests like the Decipher Bladder Genomic Classifier. They also touch upon the role of AI in pathology, the cost implications of biomarkers, and how these tools might influence future clinical practices and patient decisions. The episode emphasizes the need for precision medicine, careful patient counseling, and the impact of false positives and negatives on both patients and healthcare providers.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.